• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Capsid destabilization and epitope alterations of human papillomavirus 18 in the presence of thimerosal

    2021-11-11 13:37:52XiaofenHuangYikeLiMeifengNieMingxiYueYufangLiZhijieLinHuirongPanMujinFangTingWuShaoweiLiJunZhangNingshaoXiaQinjianZhao
    Journal of Pharmaceutical Analysis 2021年5期

    Xiaofen Huang ,Yike Li ,Meifeng Nie ,Mingxi Yue ,Yufang Li ,Zhijie Lin ,Huirong Pan , Mujin Fang , Ting Wu , Shaowei Li ,c, Jun Zhang ,Ningshao Xia ,c,**, Qinjian Zhao ,*

    a State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China

    b School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China

    c School of Life Science, Xiamen University, Xiamen, Fujian, 361102, China

    d Xiamen Innovax Biotech Company, Xiamen, Fujian, 361005, China

    Keywords:Thiol-modifying agent Monoclonal antibody Antigenicity loss Epitope-specific Conformational stability

    ABSTRACT Thimerosal has been widely used as a preservative in drug and vaccine products for decades. Due to the strong propensity to modify thiols in proteins,conformational changes could occur due to covalent bond formation between ethylmercury (a degradant of thimerosal) and thiols. Such a conformational change could lead to partial or even complete loss of desirable protein function. This study aims to investigate the effects of thimerosal on the capsid stability and antigenicity of recombinant human papillomavirus(HPV) 18 virus-like particles (VLPs). Dramatic destabilization of the recombinant viral capsid upon thimerosal treatment was observed. Such a negative effect on the thermal stability of VLPs preserved with thimerosal was shown to be dependent on the thimerosal concentration. Two highly neutralizing antibodies,13H12 and 3C3,were found to be the most sensitive to thimerosal treatment. The kinetics of antigenicity loss, when monitored with 13H12 or 3C3 as probes, yielded two distinctly different sets of kinetic parameters, while the data from both monoclonal antibodies (mAbs) followed a biphasic exponential decay model. The potential effect of thimerosal on protein function, particularly for thiolcontaining proteinaceous active components, needs to be comprehensively characterized during formulation development when a preservative is necessary.

    1. Introduction

    Thimerosal, due to its bacteriostatic and fungistatic properties,has been widely used as a preservative in formulations for biologics and drug products [1-3]. In the late 1990s, concerns were raised about whether thiomersal-containing vaccines might contribute to the development of autism and other neurodevelopmental disorders in children. However, no definitive evidence from reputable scientific studies was available to support these claims [4-7]. The WHO Consultation (April 3-4, 2012) reaffirmed the view that the benefits of using thiomersal-containing multi-dose vaccines far outweighed any risks [8]. Currently, thimerosal is still in use in several licensed vaccines, including meningococcal and multipledose seasonal influenza vaccines (Table S1), and other biological products [3].

    Having been widely used for decades as a vaccine preservative,thimerosal had been thought to be inert with respect to vaccine potency until the last 10-20 years [9]. An earlier study by Sawyer et al. [10] showed that thimerosal had deleterious effects on the potency of inactivated poliovirus vaccine (IPV) as measured by monoclonal antibody (mAb)-based enzyme-linked immunosorbent assay (ELISA), but the overall potency did not change when using a polyclonal antibody preparation.The ELISA potency based on mAbs of all three poliovirus antigens in the presence of thimerosal showed a decrease to different degrees for the different types over the observation period [10]. These studies provided the first report on the epitope-specific loss of antigenicity of a vaccine product in the presence of thimerosal. In addition, Kraan et al. [11] found that thimerosal negatively affected the antigenicity of lyophilized inactivated poliovirus vaccine by ELISA using a mixture of serotypespecific anti-poliovirus mAbs. These results showed that vaccine preservatives might result in the partial or even complete loss of antigenicity of vaccine antigens when monitored with specific mAbs.While the negative impacts on vaccine antigenicity and immunogenicity were observed, the time course of such an alteration has been poorly understood in the vaccine formulations.

    The presence of the correct conformation of protein antigens is the structural basis for vaccines to elicit functional antibodies and to confer immunity against infectious diseases.Thus,thimerosal as a preservative in vaccine formulations should be compatible with the antigens for maintaining the virion-like epitopes. Human papillomaviruses(HPVs),especially HPV16 and HPV18,are the two most common high-risk HPV types that cause cervical cancer[12].Currently, several HPV prophylactic vaccines based on virus-like particles (VLPs) have been licensed against HPV infection [13]. It has been reported that the ELISA titres in human sera of HPV VLPbased vaccine(types 16/18)preparations showed an increase upon immunization. However, the thimerosal-containing vaccine failed to induce neutralizing antibody responses [14]. In our previous study,using a mouse model,the immunogenicity of the HPV16 and HPV18 VLPs antigens in the formulation was shown to be significantly decreased in the presence of thimerosal [15].

    In this study, a panel of murine mAbs against HPV18 VLPs was assessed for its sensitivity with respect to thimerosal treatment.Two representative mAbs with the highest sensitivity to thimerosal treatment, 13H12 and 3C3, were chosen to perform the in-depth characterization of the epitope alteration with respect to the time scale of antigenicity loss and thimerosal concentration dependence.The kinetics analyses of HPV18 VLP antigenicity loss yielded unique information on the kinetic properties for the changes in immunoreactivity to these two mAbs. In addition, the decrease in binding activity to different mAbs of HPV18 VLP antigens adsorbed on aluminium-based particulate adjuvants in the presence of thimerosal was visualized using fluorescence imaging-based high content analysis.

    2. Materials and methods

    2.1. Recombinant HPV18 VLPs

    The recombinant HPV18 L1 protein was expressed inEscherichia colifrom Xiamen Innovax Biotech (Xiamen, China). The recombinant HPV18 VLPs were produced and purified according to the previously published procedures [16].The concentration of HPV18 L1 protein was measured using a bicinchoninic acid (BCA) assay(Thermo Fisher Scientific, Waltham, MA, USA) with bovine serum albumin as a standard.

    2.2. Monoclonal antibodies

    A total of 26 in-house anti-HPV18 VLPs mAbs were produced from hybridoma cell lines, provided by Xiamen Innovax Biotech and purified with a Protein A column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The concentration of the purified mAbs was determined by Ultrospec 2100 pro UV/Visible Spectrophotometer(GE Healthcare,Piscataway,NJ,USA)at 280 nm(OD 1.4 for a 1 mg/mL IgG solution). The purified 3C3 mAb was labelled with horseradish peroxidase (HRP) by a periodate conjugation method as previously reported [17].

    2.3. Human and mouse serum samples

    The serum samples derived from humans and mice for this study were reported previously [15,18]. Briefly, human serum samples (n=8) were collected from volunteers immunized with three doses of an investigational bivalent (HPV16/18) vaccine(Xiamen Innovax, Xiamen, China). Human serum samples 1-8 were numbered as 12,1,27,5,4,29,18,and 26 described by Zhang et al. [18]. Mouse serum samples (n=8) were collected from mice after 6 weeks of immunization with three doses of a thimerosalfree formulation of a pentavalent vaccine (HPV6/11/16/18/HEV).All sera-based studies were carried out in accordance with the guidelines of The Code of Ethics of the World Medical Association(Declaration of Helsinki) and approved by the Xiamen University Laboratory Animal Management Ethics Committee (XMULAC20160032) and Ethics Committee of Jiangsu Provincial Center for Disease Prevention and Control (JSJK2019-A006-02).

    2.4. Morphology and particle size of the VLPs

    Thimerosal(AR,≥98.0%,Lot No.F20110111)was purchased from Sinopharm Chemical Reagent Co.,Ltd.(Shanghai, China). A concentration of 0.01% (m/V) was the most commonly used concentration for thimerosal in vaccine formulations (Table S1). HPV18 VLPs(0.1 mg/mL) were treated with 0.01% (m/V) thimerosal for 24 h at 4°C and then treated with the same concentration of native HPV18 VLPs, applied to a carbon-coated grid and stained with 2% (m/V)uranyl acetate after removal of excess fluid.The morphologies of the HPV18 VLPs were examined using a JEM2100HC transmission electron microscope(JEOL,Tokyo,Japan)operated at 120 kV.

    Table 1 Conformational stability analysis of HPV18 VLPs upon thimerosal treatment detected by DSF. The Tm values were measured in three independent replicates.

    Table 2 Characteristics of a panel of HPV18 murine monoclonal antibodies and their relative binding activity to thimerosal treated VLPs (rEC50 = EC50 (thimerosal-treated)/EC50 (control))compared to the control.

    2.5. Thermal stability by differential scanning fluorimetry (DSF)and cloud point analysis

    DSF[19,20]was carried out by a real-time PCR instrument,Bio-Rad T100? Thermal Cycler (Hercules, California, USA). First,200 μg/mL HPV18 VLPs were treated with different concentrations(0%,0.001%,0.005%,0.01%,0.02%,and 0.05%(m/V))of thimerosal for 24 h at 4°C.The fluorescent dye,SYPRO Orange(Sigma-Aldrich,St.Louis,MO,USA),was diluted 50×from its stock concentration using deionized water and then mixed at a volume ratio of 1:9 of the antigens to thimerosal. Subsequently, 50 μL of the mixed solution was added to each well of the plate.Then,the PCR plate was sealed and centrifuged at 1000 rpm for 1 min.The real-time PCR machine was used to heat the samples at intervals of approximately 0.5°C ramping from 10°C to 90°C. Fluorescence emission was collected using a HEX filter (560 nm-580 nm). Melting curves of fluorescence intensity at 570 nm were obtained with a Bio-Rad CFX Manager. The transition midpoint temperature (Tm) values were determined by derivative analysis using the software package OriginPro 9.1 (Origin Lab Corp., Northampton, MA, USA). Each sample was determined by triplicate measurements. The cloud point with temperature ramping was determined by turbidity measurements with a UV2100PRO, which was equipped with an external Peltier thermal controller in the temperature range of 30-90°C. The samples were measured at a concentration of 0.1 mg/mL L1 protein. The optical density at 350 nm was used to detect the signals due to protein aggregation.

    Fig.1.Characterization of the morphology and thermal stability of HPV18 VLPs with or without thimerosal treatment. (A) The morphologies of the control and 0.01% (m/V)thimerosal-treated HPV18 VLPs.(B)The thermal stability of VLP antigens treated with different concentrations of thimerosal as monitored by DSF[19,20].Tm differences were across the range from 50.0 °C(0.05%(m/V)thimerosal-treated)to 75.5 °C(control).(C)The cloud point temperatures of thimerosal-treated and control VLPs were approximately 43 °C and 71 °C, respectively.

    2.6. Comparative study of polyclonal antibody binding activity to VLPs

    First,80 μg/mL HPV18 VLPs were pre-incubated in the presence of 0.01% (m/V) thimerosal for 24 h at 25°C. Then, the microplates were coated at 25°C for 2 h with 100 ng/well VLPs with or without thimerosal treatment. After plate blocking, the plates were incubated at 25°C for 1 h with 100 μL of 2-fold serial dilutions of human serum and 150 μL of 3-fold serial dilutions of mouse serum diluted with assay diluent.After 5 wash cycles,a goat-anti-mouse or goatanti-human IgG horseradish peroxidase (HRP) conjugated at 1:5000(V/V)was added to the plates and incubated for 1 h at 25°C.Subsequently,100 μL per well tetramethyl benzidine substrate solution (Beijing Wantai Biological Pharmaceutical Co., Ltd., Beijing,China) was added and incubated for 10 min at 25°C. The reaction was stopped by adding 50 μL of 2 M sulfuric acid per well,and the intensity in the well was measured at 450 nm against 630 nm as the background. The binding activity of the control or thimerosal treated VLPs was defined as the antibody dilution required to achieve 50% of the maximal signal (ED50). The relative ED50(ED50(control)/ED50(thimerosal-treated)) was used to measure the relative binding activity of the polyclonal antibody to HPV18 VLPs.

    2.7. The mAb binding activity to the VLPs with or without thimerosal treatment

    Direct binding ELISA was used to evaluate the median effective concentration (EC50) of mAbs in solution against the surfaceimmobilized recombinant HPV18 VLPs with or without thimerosal treatment.Some VLPs(80 μg/mL)were treated with 0.01%(m/V)thimerosal for 24 h at 4°C.Then,the microplates were coated at 25°C for 2 h with 100 ng/well VLPs with or without thimerosal treatment. After plate blocking, the plates were incubated and maintained at 25°C for 1 h with 100 μL of 2-fold serial dilutions(starting with 1 μg/mL mAbs) of 26 different mAbs using assay diluent. The binding activity of the control VLPs or thimerosaltreated VLPs was defined as the antibody concentration required to achieve 50% of the maximal signal (EC50, ng/mL). The relative EC50(EC50(thimerosal-treated)/EC50(control)) was used to measure the relative binding activity for mAbs to HPV18 VLPs coated on ELISA plates.

    2.8. Surface plasmon resonance (SPR) for antigenicity analysis

    The SPR technique was employed to assess the antigenicity of HPV18 VLPs using a Biacore 3000 instrument (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) with similar procedures as previously described[21].Briefly,80 μg/mL VLPs were pre-incubated in the presence of thimerosal at different concentrations(0%,0.001%,0.005%, 0.01%, and 0.02% (m/V)), diluted to 20 μg/mL and detected in-cycle for 24 h at 25°C. Two mAbs (3C3 and 13H12, 30 μg/mL)were captured by chemically immobilized GAM-Fc on the chip surface with HBS-EP running buffer (0.01 M HEPES, 0.5 M NaCl,3 mM EDTA, 0.005% (V/V) Tween-20, pH 7.4). The HPV18 VLPs treated with thimerosal subsequently flowed through the chip surface binding to the captured mAbs.The relative antigenicity was calculated by normalizing the rRU (RUAg/RUAb) of the thimerosaltreated VLPs in a flow cell(0%,0.001%,0.005%,0.01%,and 0.02%(m/V)) to that of the control HPV18 VLPs in a separate flow cell in the same assay cycle.

    2.9. Sandwich ELISA for VLP antigenicity analysis

    Sandwich ELISA was utilized to determine the antigenicity of the HPV18 VLPs with 0.01% (m/V) thimerosal treatment compared to the control for 24 h at 4°C. The 96-well micro-plate was coated with the mAb 13H12 as the capture antibody (100 ng per well) at 4°C overnight. After plate coating and blocking, a set of eleven serial two-fold dilutions of HPV18 VLPs with or without thimerosal treatment,starting at 4 μg/mL,were added and incubated at 25°C for 1 h. Then, 100 μL of mAb 3C3 labelled with HRP used as the detection antibody diluted 1:3000(V/V)in assay diluent was added and incubated at 25°C for 1 h.

    2.10. The antigenicity of VLP thimerosal containing vaccine detected by imaging-based high content analysis (HCA)

    Fig.2.The altered antigenicity of HPV18 VLPs to antibodies in human or mouse serum.Human and mouse serum samples were taken after post immunization using intact HPV18 VLPs based vaccines. (A) Human-7 and mouse-4 were the serum samples that showed the highest sensitivity to thimerosal treatment. The binding activities of eight different human and mouse serum samples to VLP antigens with and without thimerosal treatment are shown in Figs. S2 and S3. (B) Binding activity of eight different human and mouse serum samples to the control or thimerosal-treated VLPs (ED50) which is the serum dilution fold required to achieve 50% of the maximal signal. (C) The relative binding activity(rED50 = ED50 (control)/ED50 (thimerosal-treated)) of eight different human and mouse serum samples to thimerosal-treated VLPs.

    An Opera Phenix high content system (PerkinElmer, Wellesley,MA, USA) and fluorescence plate reader (Beckman Coulter, Inc.,Brea, CA, USA) were used for the antigenicity analysis of HPV18 antigens adsorbed on aluminium-based adjuvants. VLPs (160 μg/mL) were preincubated with 0.02% (m/V) thimerosal at 25°C for approximately 30 min, and then the adjuvant was added to the antigen solution at a volume ratio of 1:1 and mixed sufficiently.Then,the solution was kept at 4°C for 24 h before testing.The final concentration of thimerosal was 0.01%(m/V),and the concentration of Al was 420 μg/mL. Two murine mAbs, 13H12 and 3C3, were labelled by DyLight 488 Amine-Reactive Dye (Pierce/Thermo Scientific,Rockford,IL,USA)according to the instructions.These mAbs were used to detect the antigenicity of the VLP antigens in the fluorescence immunoassay.The antigenicity of antigens is based on the measurement of total fluorescence intensity of HCA or using a plate reader to measure the thimerosal-treated VLPs compared to the control.

    2.11. Statistical analysis

    EC50values of ELISA and HCA data were calculated using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). For kinetics studies, a double exponential equation was fitted to the Biacore data using the software package OriginPro 9.1.

    3. Results

    3.1. The morphology and thermal stability of VLPs in the presence of thimerosal

    The transmission electron microscope (TEM) images showed that the HPV18 VLPs with thimerosal treatment were morphologically similar to the control and did not show any observable VLP aggregates or significant deformation of the spherical particles(Fig. 1A). However, the thermal stability of the HPV18 VLPs upon thimerosal treatment was dramatically reduced as reflected by a lower transition temperature by DSF or a lower cloud point for thermally induced aggregate formation.Tmof the control group was 75.5°C, while theTmfor thimerosal-treated HPV18 VLPs decreased from 74.5°C to 50.2°C (Table 1, Figs. 1B and S1), a reduction of 25.3°C in the transition temperature (Table 1). The cloud point was defined as the temperature when the discrete VLPs began to agglomerate as monitored at a given wavelength by the light scattering signals due to larger particle formation. The cloud point temperatures of HPV18 VLPs with or without thimerosal treatment were approximately 43°C and 71°C, respectively(Fig.1C). The observed difference of 28°C indicated that the VLPs treated with thimerosal have a much stronger propensity to aggregate during heat stress,indicating dramatic destabilization of the recombinant viral capsid.

    3.2. Polyclonal antibody binding activity to VLPs with thimerosal treatment

    Fig.3.The amplitude of changes to coating antigens reflected upon thimerosal treatment.The binding ability of HPV18 VLPs with or without thimerosal treatment to the mAbs was measured by direct binding ELISA. (A) The binding profiles of three representative mAbs (13H12,14E9 and 11A3) to 0.01% (m/V) thimerosal-treated HPV18 VLPs compared to the control are shown.(B)The correlation between the binding affinity and the sensitivity to thimerosal treatment of VLPs for different mAbs.This figure was derived from Figs.S4A and B.

    HPV18 VLPs antigens as coating antigens, with or without thimerosal treatment,were used to measure the binding activity of the serum samples from animals or humans immunized with control VLPs.The activity of the polyclonal antibodies in the serum samples was shown to decrease to varying degrees upon treatment with the coating antigens(Figs.2A and B,S2 and S3).The amplitude of change was more pronounced for the mouse serum samples.When compared to the control coating antigen, the relative binding activity (rED50=ED50(control)/ED50(thimerosal-treated)) of the thimerosal-treated antigen on the plate showed an average 6-fold reduction in the mouse serum group and a 2.5-fold decrease in the human serum group (Fig. 2C). These results indicated that the epitopes in the recombinant HPV 18 capsid are somehow altered upon thimerosal treatment,lowering the binding of native antigenelicited antibodies when the assays were performed in parallel using two different coating antigens.

    3.3. The effects of thimerosal on VLP antigenicity

    3.3.1. Varying degrees of mAb sensitivity to thimerosal-treated HPV18 VLPs

    As shown in Table 2 [18,22] and Fig. S4A, the degree of sensitivity of a panel of 26 mAbs to thimerosal-treated HPV18 VLPs was ranked and categorized into four different groups according to the corresponding fold change in relative EC50(rEC50=EC50(thimerosal-treated)/EC50(control)) values. The majority of mAbs were shown to have decreased (Groups I and II in Table 2) or similar binding activity(Group III in Table 2)upon thimerosal treatment.In particular,upon thimerosal treatment, the binding activity of 13H12 and 3C3 to HPV18 VLPs showed a reduction of up to 20-to 30-fold.A small portion of the mAbs showed a slight increase in binding activity to thimerosal-treated VLP antigens(e.g.,11A3 in Fig.3A and Table 2).Not surprisingly,the sensitivity to thimerosal-treated VLPs showed no apparent correlation to their affinity to VLP antigens (Fig. S4B),as the thimerosal-treated changes may be unique for any given mAb due to the nature and uniqueness of the epitope it recognizes.13H12 and 3C3, the two VLPs highly sensitive to thimerosal treatment, are also elite virus neutralizers (NC50<10 ng/mL), top binders to the VLPs and highly conformation-dependent. This would suggest that the epitopes sensitive to thimerosal treatment are also likely to be clinically relevant epitopes. In contrast, 9F5, a high affinity antibody with no virus neutralization capacity, exhibited no sensitivity to thimerosal-treated VLPs(Fig. 3B).

    3.3.2. Thimerosal concentration dependence of the antigenicity reduction

    Fig.4.The ELISA binding activity of two mAbs(13H12 and 3C3)to VLP antigens after pretreatment with thimerosal.(A)The binding profiles of two mAbs(13H12 and 3C3)to VLP antigens treated with 0.01%(m/V)thimerosal at different time points.(B)rEC50 values at different processing time points treated with different thimerosal concentrations.(C)The antigenicity of VLPs was measured by two mAbs (capture: 13H12, detection: 3C3-HRP) using a sandwich ELISA.

    As presented in Figs.4A and B,the OD450curves clearly showed a time-dependence (up to 48 h tested) and thimerosal concentration dependence. However, the decreasing trends in antigen binding to two mAbs (3C3 and 13H12) appeared to be unique for each mAb (Fig. 4B). For 3C3, the plateauing effect appeared at higher thimerosal concentrations.These results indicated that mAb 13H12 was more sensitive than 3C3 to thimerosal treatment at intermediate thimerosal concentrations(i.e.,0.005%and 0.01%(m/V))(Fig.4B).In addition to the one-site binding assays,the relative antigenicity was also measured quantitatively by two mAb-based(capture: 13H12, detection: 3C3) sandwich ELISA assays. The EC50values showed a 12-fold increase from 83 ± 1.1 ng/mL to 992 ± 1.1 ng/mL, when the VLPs were treated with thimerosal,indicating substantial weakening of the VLPs binding to these mAbs(Fig. 4C).

    3.3.3. The kinetics of epitope-specific antigenicity loss

    The sensor chip based SPR method was used to study the kinetics of HPV18 VLPs antigenicity alteration upon thimerosal treatment. SPR binding signals can be monitored in real time without need for labelling of either of the binding partners.Fig.5A is a schematic diagram showing the detection principle of the SPR sensorgram using mAbs as molecular probes. The biphasic loss of antigenicity (normalized to the control at every time point) of the VLPs due to thimerosal treatment is compared to that of a control sample(left panel of Fig.5B).The data were then fitted reasonably well to a double exponential decay model in the right panel of Fig. 5B with the parameters from the fitting tabulated in Table S2.The loss of antigenicity of VLP antigens occurred in a thimerosal concentration dependent manner (Fig. 5C). The relative antigenicity of 3C3 and 13H12 to VLPs by 0.01%(m/V)thimerosal treatment was reduced by approximately 70%-80% in the first 24 h. The antigenicity loss by SPR was also agreeable with the data obtained from the direct binding ELISA where the VLPs, with or without thimerosal treatment,were coated on the plate(Fig.4B).As shown in Table S2, the majority of antigenicity loss occurred in the fast phase, with an Afast/(Afast+ Aslow) ratio of 0.65 or higher for mAb 13H12 in the middle-and high-dose groups(≥0.005%(m/V)),while the ratio was observed for 3C3 in the low-dose groups(≤0.005%(m/V)). Thekfastof the antigenicity loss of VLPs to 13H12 was approximately 5-50 times higher in the lowest-dose group(0.001%(m/V))than in the middle-or high-dose groups(≥0.005%(m/V)).For 3C3,thekfastin the lowest-dose group (0.08 ± 0.007 min-1) was only 3.0-3.5 times higher than that in the middle-or high-dose groups(Table S2).Thekfastvalues of both mAbs 13H12 and 3C3 were very close in the high-dose groups(≥0.01%(m/V)),which could indicate a large excess of ethylmercury, so the modification of the thiol (s)followed pseudo-first-order kinetics.

    Fig.5.The kinetics of HPV18 VLPs antigenicity loss as measured by SPR.(A)Schematic diagram showing the SPR measurement process.The binding activities of mAbs to the native and thimerosal-treated VLPs were measured at different times,and the binding cycles were repeated for 24 h.Each cycle for the binding activity yielded a data point.(B)In the left panel of Fig. 5B, the relative antigenicity of HPV18 VLPs with different concentrations of thimerosal treatment was measured by the mAbs 13H12 and 3C3. The kinetics of antigenicity loss upon thimerosal treatment was fitted to a double exponential equation,F(t)=Afast·exp(-kfast t)+Aslow·exp(-kslow t)+C,and is shown in the right panel of Fig.5B.In the inset, the first 4 h of the kinetics of antigenicity loss of VLPs is shown. (C) Dose-response relationship between the binding capacity and thimerosal concentration.

    3.4. Visualization of the thimerosal-induced reduction in VLP antigenicity

    As reported in the previous sections,the antigenicity in solution was measured by a one-site or two-site binding assay based on mAbs. Most vaccines are adjuvanted, containing the particleadsorbed antigens in the formulation. In this part, an in situ method (HCA) was developed for visualizing and evaluating the antigenicity of VLP antigens adsorbed on micrometre-scale aluminium-based adjuvants in the presence of thimerosal. The distribution of fluorescence signals from the labelled mAbs on adjuvant particles with the adsorbed VLP antigen was clearly observed. The binding activity of mAbs 13H12 and 3C3 to the thimerosal-treated VLP antigen adsorbed on the adjuvant was shown to decrease according to the changes in fluorescence intensity owing to the labelled mAbs(Fig.6A).The antigenicity of VLP antigens in the presence of thimerosal was expressed by the EC50values, which was approximately 7- and 5-fold higher than their control groups for these two mAbs tested(Fig.6B).The magnitude of change observed on the surface adsorbed antigen using these two mAbs separately was also in agreement with the antigenicity loss (approximately one order of magnitude) from the sandwich ELISA, where these two mAbs were used as capture (13H12) and detection (3C3) antibodies, respectively(Fig. 4C).

    4. Discussion

    In our previous studies, structural alterations were observed in HPV18 VLPs with thimerosal treatment via cryo-electron microscopy and three-dimensional reconstruction of the recombinant viral capsid. The reduction of immunogenicity of HPV16/18 due to thimerosal treatment was also demonstrated by the overall antibody or neutralizing antibody, as well as with epitope-specific competition. Covalent modifications of proteins by thimerosal may be the underlying mechanism for conformational changes that lead to reduced immunogenicity[15].Among the four types of HPV studied (6, 11, 16 and 18), HPV 16 and 18 (type 18 in particular)showed the most prominent effects on structure and function due to the presence of the commonly used preservative thimerosal[15].In the present study, we focused on capsid destabilization and antigenicity changes probed with a panel of murine mAbs of the recombinant HPV 18 viral capsid. Similarly, it has been reported that the epitope for a well-studied neutralizing mAb, mAb H16.V5 against HPV16 L1 VLP, was destroyed after incubation with thimerosal[14].Like H16.V5 for HPV16,both 13H12 and 3C3 used in this study, are highly neutralizing mAbs for HPV18. These observations warrant more cautions on thimerosal use for protein based vaccines.

    Therefore,the widely used vaccine preservative thimerosal may be not‘inert’with respect to the structure and function of the active protein components in drug or vaccine formulations. Recently,Strohmidel et al. [23] found the covalent binding between the EtHg+derived from thimerosal and haemagglutinin of a seasonal tetravalent influenza vaccine.The thiol-containing vaccine antigens are likely to be modified,as thimerosal is a specific thiol-capping or thiol-reactive agent. In this study, dramatic capsid destabilization of HPV18,probably due to thiol modification(s)at some accessible site(s),was demonstrated with the substantially reduced transition temperature in protein thermal unfolding by 25.3°C and by 28.7°C from the cloud point measurement with an enhanced propensity to aggregate upon thermal stress (Table 1 and Fig. 1C). In terms of function,a panel of mAbs showed varying degrees of alterations in binding activity to the HPV18 VLPs antigens upon thimerosal treatment.Specifically,the two mAbs(13H12 and 3C3)that showed the highest sensitivity to thimerosal treatment are also typespecific with high virus neutralizing efficiency. The kinetic differences in the antigenicity loss when monitored with these two distinctly different mAbs(13H12 and 3C3)would indicate that the loss of immunoreactivity is epitope-specific. Both the ELISA(measuring the immunocomplexes at a given equilibrium)and the SPR-based kinetic binding assay (measured in real time with no wash steps) yielded similar conclusions for the thimerosal concentration dependence and the epitope-specific manner of the antigenicity changes.

    Fig.6.Visualization of the VLP antigenicity decreases in the presence of thimerosal. (A) HCA images of the antigenicity of mAbs 13H12 and 3C3 to HPV18 VLPs adsorbed on aluminium adjuvants in the presence of thimerosal or absence of thimerosal.The intensity of fluorescence in only part of the whole visual field was read by the Opera Phenix high content system.(B)The antigenicity of VLP antigens with or without thimerosal treatment was analysed by a fluorescence plate reader.The EC50 means the concentration of antigen required to achieve 50% of the maximal signal.

    The phenomenon of epitope alterations in the presence of thimerosal has been reported for other vaccines. Kraan et al. [11]reported that the presence of thimerosal resulted in a temperaturedependent loss of polio D-antigen by D-antigen ELISA using a mixture of serotype-specific anti-poliovirus mAbs.D-antigen could be recovered by addition of L-cysteine into the thimerosalcontaining vaccine formulation, probably through the regeneration of some critical thiol group(s)by the incoming free thiols in the form of overwhelming amount of cysteine. Similarly, a significant reduction was observed in its immunoreactivity by using a specific mAb-based assay for a thimerosal-containing formulation of glycoprotein 63 fromLeishmaniaafter one year of storage at 4°C[24]. The findings presented by Harmsen et al. [25] showed that thimerosal could stimulate intact (146S) foot-and-mouth disease virions to dissociate into 12S particles when monitored with mAbbased ELISA. Such dissociation could result in strongly reduced immunogenicity.

    Although alterations in the antigenicity and immunogenicity of vaccine antigens had been observed,the in-depth characterization of the kinetics of the thiol modification of antigens was not previously available. The kinetics of epitope modification could vary because the reactivity and accessibility of the thiol groups could differ significantly. It has been reported that the antigenicity of poliovirus type 2 was unchanged when ELISA was performed with monoclonal 9Ab after thimerosal incubation for 1 h at 25°C.However, the other mAb (monoclonal 7Ab) based potency of poliovirus type 2 was completely lost within 5 min of incubation with thimerosal at 25°C or 37°C [10]. In this study, the SPR data showed that the half-life of the relative antigenicity loss for either 13H12 or 3C3 was approximately 6 or 9 h based on thekslowat 25°C upon thimerosal treatment. If the HPV vaccine formulation contained 40 μg of HPV18 L1 proteins in a 0.5 mL dose containing 0.01%thimerosal,the mole ratio of Hg+from thimerosal to cysteines(14)in the HPV18 L1 proteins was 11(0.125 μmol:0.0112 μmol).If only one cysteine is accessible for forming a covalent bond with an incoming EtHg+,the molar ratio would be 150.The presence of an overwhelming excess of ethylmercury compared to the target thiol group(s) also explained the good fits using the biphasic pseudofirst-order kinetics model for the antigenicity loss data obtained after monitoring with two mAbs(Fig.5B and Table S2).In addition,it has been reported that the mercury(II) tightly bonds to the histidine imidazole tightly and thekfast(13.28 ± 0.07 min-1) is approximately one or two orders of magnitude higher than thekfastfrom SPR data (0.02-1.2 min-1) [26]. The kinetics results of antigenicity loss should rule out the binding to the imidazole of histidine residues to be the basis for immunoreactivity change, as this would be a much faster event.Thiol modification is likely to be the underlying chemical events, causing impairments in clinically relevant epitopes.

    Thimerosal can spontaneously degrade into thiosalicylic acid and ethylmercury in aqueous media.The strong affinity of mercuric ions (Hg2+) and their alkyl derivatives towards sulfhydryl groups(-SH) in amino acids, peptides and proteins is well documented[27-29].An in vivo study in humans performed by Trümpler et al.[30]reported the observation of ethylmercury-glutathione adducts.They also investigated the interaction between β-lactoglobulin A and thimerosal in simulated physiological conditions (pH 7.4, at 37°C) for 1 h, and the results showed that a free thiol residue in peptide T13 (amino acids 104-124) is the binding site of ethylmercury by means of LC/ESI-TOF-MS and LC/ICP-MS[31].Hogeback et al.[32]studied the adduct formation of organic mercury species with carbonic anhydrase and heamoglobin,and found that the free cysteine residues within proteins are the binding sites of methylmercury and ethylmercury cations. Janzen et al. [33] also showed that the binding stoichiometry correlates with the number of free thiols in the α- and β-chains of heamoglobin. In addition, thimerosal forms a bovine serum albumin-ethylmercury adduct with thiosalicylic acid release through the free Cys 34 residue and changes the conformation of bovine serum albumin[34].In another study, Ishii et al. [35] found that HPV16 pseudovirions lose their infectivity to HeLa cells after incubation with thiol-reactive reagents.It has been demonstrated that HPV16 L1 protein-free thiols in C146, C225 and C229 are accessible to thiol reactive agents by mass spectrometry and mutational analysis. The capping of these thiols or ethylmercury-cysteine adduct formation might result in reduced infectivity[35].Since sulfhydryl modifications via covalent bonding should be responsible for the epitope alteration of the HPV18 viral capsid, further efforts are needed to identify the specific cysteine residue(s)involved in the thiol modification of HPV18 VLPs antigens in the presence of thimerosal.

    Currently, although thimerosal-free single-dose vials and peadiatric vaccines are required,a preservative is still necessary in multi-dose vials of influenza vaccines (Table S1). Therefore,choosing thimerosal as a preservative for future use needs to be carefully studied based on its molecular structure, especially for thiol-containing proteins in vaccines and other biological products.In-depth characterization should be performed on the potential impact to the antigen structures and, even more importantly, its functions such as antigenicity and immunogenicity. Recently,Agarwal et al. [36] found that thimerosal destabilizes aluminiumbased adjuvant adsorbed recombinant subunit rotavirus vaccine antigens and induces loss in immunoreactivity as reflected by mAbbased ELISA binding ability. If thimerosal is used in bioprocessing procedures,free cysteine could be used later in the process for the regeneration of the critical cysteine residues,reversing some of the effects incurred due to the presence of thimerosal. In addition,alternative preservatives, such as 2-phenoxyethanol, which have been used in pneumococcal multi-dose vaccine formulations [37],should be considered for use in vaccine formulations when thimerosal is incompatible with the target antigens.

    5. Conclusions

    This study significantly advanced our understanding on the kinetics and nature of thiol-modifications by thimerosal, leading to partial or even complete loss of antigen function. Epitope-specific alterations in the antigenicity of HPV18 VLPs were characterized using a set of mAb-based immunochemical assays after thimerosal exposure. Deleterious effects of thiol-reactive thimerosal on the antigenicity and protein conformational stability of HPV18 VLPs were demonstrated in a thimerosal concentration-dependent manner with the time scale of antigen modifications defined. The kinetics of antigenicity loss due to thimerosal treatment was monitored with two different mAbs, showing distinctly different sets of kinetic parameters. Thiol modification may be the underlying event that results in the loss of antigenicity of HPV18 VLPs,coupled with structural alterations and substantially reduced protein stability.Efforts should be made in an in-depth understanding of the process and formulation with respect to the presence and maintenance of the clinically relevant epitopes on the vaccine antigen during vaccine bioprocessing, formulation and transportation.

    Declaration of competing interest

    The authors declare that there are no conflicts of interest.

    Acknowledgments

    This work was funded by the National Natural Science Foundation of China (Grant Nos.: 81993149041, and U1705283), the National Science and Technology Major Project, China (Project No.:2018ZX09303005-002), Fujian Health Education Joint Research Project, China (Project No.: 2019-WJ-05) and Xiamen Science and Technology Major Project, China (Project No.: 3502Z20193009).We are grateful to Mr.Yibin Zhu,Mrs.Yue Zhang,Mr.Zhenqin Chen,Mr.Qingbing Zheng,and Mr.Yang Huang for their technical assistance.

    Appendix A. Supplementary data

    Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpha.2020.08.007.

    久久久午夜欧美精品| 国产日韩欧美亚洲二区| 久久综合国产亚洲精品| 国产精品无大码| 国产成人精品一,二区| 色婷婷久久久亚洲欧美| 亚洲内射少妇av| 在线观看av片永久免费下载| 夜夜爽夜夜爽视频| 久久精品夜色国产| 97超视频在线观看视频| 欧美最新免费一区二区三区| 久久久久久久久久久丰满| 2021少妇久久久久久久久久久| 亚洲自拍偷在线| 欧美高清性xxxxhd video| 国产精品久久久久久精品电影小说 | 国产精品成人在线| 人人妻人人爽人人添夜夜欢视频 | 欧美日韩亚洲高清精品| 午夜老司机福利剧场| 国国产精品蜜臀av免费| 亚洲内射少妇av| 欧美日韩在线观看h| 伊人久久精品亚洲午夜| 国产av国产精品国产| 看免费成人av毛片| 最近最新中文字幕大全电影3| 简卡轻食公司| 国产精品女同一区二区软件| 亚洲国产av新网站| 国内精品美女久久久久久| 久久久欧美国产精品| 成人二区视频| 一区二区三区乱码不卡18| 男女边吃奶边做爰视频| 国产极品天堂在线| 五月开心婷婷网| 美女被艹到高潮喷水动态| 老司机影院成人| 亚洲精品久久午夜乱码| 中文精品一卡2卡3卡4更新| 日韩av在线免费看完整版不卡| 精品国产一区二区三区久久久樱花 | 波野结衣二区三区在线| 青春草视频在线免费观看| 91精品国产九色| 男人爽女人下面视频在线观看| 能在线免费看毛片的网站| 久久97久久精品| 青春草亚洲视频在线观看| 视频区图区小说| 久久国产乱子免费精品| 亚洲精品自拍成人| 午夜免费观看性视频| 国产精品99久久99久久久不卡 | 成人综合一区亚洲| 性色av一级| 嫩草影院入口| 国产国拍精品亚洲av在线观看| 欧美亚洲 丝袜 人妻 在线| 国产精品一区二区在线观看99| 欧美日韩亚洲高清精品| 久久人人爽人人片av| 深爱激情五月婷婷| 一区二区av电影网| 精品人妻视频免费看| 精品久久久久久久久亚洲| 成人亚洲精品一区在线观看 | 久久人人爽av亚洲精品天堂 | 少妇人妻久久综合中文| 国产爱豆传媒在线观看| 岛国毛片在线播放| 精品久久久久久久人妻蜜臀av| 高清毛片免费看| 五月天丁香电影| 亚洲婷婷狠狠爱综合网| 嫩草影院精品99| 国产精品国产三级国产av玫瑰| av在线观看视频网站免费| 欧美最新免费一区二区三区| 久久亚洲国产成人精品v| 男女那种视频在线观看| 日本一本二区三区精品| 日本一二三区视频观看| 99九九线精品视频在线观看视频| 69人妻影院| 校园人妻丝袜中文字幕| 国产av不卡久久| 哪个播放器可以免费观看大片| 欧美精品人与动牲交sv欧美| 一个人看的www免费观看视频| 亚洲色图av天堂| 国产一区二区三区综合在线观看 | 中文天堂在线官网| 国产精品99久久久久久久久| 免费黄网站久久成人精品| 日韩一区二区三区影片| 国产中年淑女户外野战色| 久久久久精品性色| 色视频www国产| 国产乱来视频区| 狂野欧美激情性bbbbbb| 最近手机中文字幕大全| 中文字幕av成人在线电影| 又黄又爽又刺激的免费视频.| 国产欧美日韩一区二区三区在线 | 高清av免费在线| 18禁裸乳无遮挡动漫免费视频 | 少妇 在线观看| 国产亚洲精品久久久com| 日韩欧美精品免费久久| 久久99热这里只频精品6学生| 少妇的逼好多水| 草草在线视频免费看| 青青草视频在线视频观看| 亚洲在线观看片| 97在线人人人人妻| 三级国产精品片| 国产中年淑女户外野战色| 国产精品99久久99久久久不卡 | 老司机影院毛片| 人人妻人人澡人人爽人人夜夜| 日本免费在线观看一区| 亚洲,欧美,日韩| 小蜜桃在线观看免费完整版高清| 精品一区二区三卡| 亚洲在线观看片| 亚洲av成人精品一区久久| 又爽又黄无遮挡网站| 久久精品夜色国产| 成年人午夜在线观看视频| 亚洲国产精品成人综合色| 卡戴珊不雅视频在线播放| 日韩大片免费观看网站| 免费播放大片免费观看视频在线观看| 在线观看一区二区三区| 在线观看三级黄色| 国国产精品蜜臀av免费| 日本猛色少妇xxxxx猛交久久| 久久99热这里只有精品18| av在线观看视频网站免费| 男人舔奶头视频| 久久99蜜桃精品久久| av免费观看日本| 黑人高潮一二区| 国产精品三级大全| 久久久国产一区二区| 亚洲内射少妇av| 在线观看三级黄色| 国产成人福利小说| 麻豆国产97在线/欧美| 免费不卡的大黄色大毛片视频在线观看| 国产精品久久久久久精品电影| 搡女人真爽免费视频火全软件| 99久久中文字幕三级久久日本| 久久99蜜桃精品久久| 国产黄频视频在线观看| 街头女战士在线观看网站| 国产 一区精品| 日韩国内少妇激情av| 99精国产麻豆久久婷婷| 九九在线视频观看精品| 精品国产露脸久久av麻豆| 在线天堂最新版资源| 人体艺术视频欧美日本| 美女脱内裤让男人舔精品视频| 三级男女做爰猛烈吃奶摸视频| 亚洲国产高清在线一区二区三| 肉色欧美久久久久久久蜜桃 | 高清av免费在线| 国产国拍精品亚洲av在线观看| 大片电影免费在线观看免费| 精品午夜福利在线看| 爱豆传媒免费全集在线观看| 高清日韩中文字幕在线| 国产精品久久久久久精品电影| 久久99热这里只有精品18| 精品一区二区免费观看| 国产精品av视频在线免费观看| 精品久久久久久电影网| av免费在线看不卡| 一级毛片 在线播放| 在线观看三级黄色| 舔av片在线| 最近中文字幕高清免费大全6| 一区二区三区四区激情视频| 成年人午夜在线观看视频| 免费看av在线观看网站| 久久久久久久大尺度免费视频| 晚上一个人看的免费电影| 欧美极品一区二区三区四区| 免费看光身美女| 久久精品熟女亚洲av麻豆精品| 可以在线观看毛片的网站| 亚洲精华国产精华液的使用体验| 日韩在线高清观看一区二区三区| 欧美老熟妇乱子伦牲交| 精品酒店卫生间| 少妇高潮的动态图| 日本黄大片高清| 寂寞人妻少妇视频99o| freevideosex欧美| 欧美亚洲 丝袜 人妻 在线| 99热网站在线观看| 夫妻午夜视频| 久久久久久久精品精品| 好男人在线观看高清免费视频| 久久人人爽人人片av| 蜜桃亚洲精品一区二区三区| 国产精品久久久久久久久免| 欧美高清性xxxxhd video| 久久久a久久爽久久v久久| kizo精华| 黄色日韩在线| av在线蜜桃| av播播在线观看一区| 免费观看a级毛片全部| 99热国产这里只有精品6| 亚洲最大成人av| 色播亚洲综合网| 简卡轻食公司| 尤物成人国产欧美一区二区三区| 亚洲丝袜综合中文字幕| 麻豆成人av视频| 国产永久视频网站| 精品国产三级普通话版| 久久久久久国产a免费观看| 视频中文字幕在线观看| 国语对白做爰xxxⅹ性视频网站| 国产成人aa在线观看| 涩涩av久久男人的天堂| 国产淫语在线视频| 内射极品少妇av片p| 欧美激情国产日韩精品一区| 免费观看av网站的网址| 欧美亚洲 丝袜 人妻 在线| 欧美另类一区| 18禁在线无遮挡免费观看视频| 国产精品国产三级国产专区5o| 国产成人a区在线观看| 不卡视频在线观看欧美| 国产真实伦视频高清在线观看| 亚洲国产欧美在线一区| 欧美性感艳星| 性色avwww在线观看| 人妻系列 视频| 欧美成人午夜免费资源| 精品久久久噜噜| 九草在线视频观看| 永久免费av网站大全| 国产 一区精品| av又黄又爽大尺度在线免费看| 青春草亚洲视频在线观看| 丰满少妇做爰视频| 日韩 亚洲 欧美在线| 超碰97精品在线观看| 别揉我奶头 嗯啊视频| 黄色欧美视频在线观看| 在线精品无人区一区二区三 | 亚洲人成网站在线播| 欧美高清成人免费视频www| 中国美白少妇内射xxxbb| 亚洲经典国产精华液单| 国产亚洲5aaaaa淫片| 国产成年人精品一区二区| 听说在线观看完整版免费高清| 亚洲欧美清纯卡通| 久久久久久久国产电影| 欧美变态另类bdsm刘玥| 天堂中文最新版在线下载 | 听说在线观看完整版免费高清| 欧美zozozo另类| 国产亚洲精品久久久com| 久久精品国产亚洲网站| 真实男女啪啪啪动态图| 在线a可以看的网站| 天天躁夜夜躁狠狠久久av| 国产黄a三级三级三级人| 六月丁香七月| 在线亚洲精品国产二区图片欧美 | 成人一区二区视频在线观看| 欧美人与善性xxx| 寂寞人妻少妇视频99o| 亚洲国产av新网站| 最近手机中文字幕大全| 亚洲在线观看片| 欧美精品一区二区大全| 日韩中字成人| 久久久精品94久久精品| 99久久精品国产国产毛片| 日韩国内少妇激情av| 高清午夜精品一区二区三区| 国产黄频视频在线观看| 国产国拍精品亚洲av在线观看| 天天躁日日操中文字幕| 人妻系列 视频| 欧美97在线视频| 精品酒店卫生间| 国产黄色免费在线视频| 一本色道久久久久久精品综合| 国产精品女同一区二区软件| 久久久色成人| 亚洲av在线观看美女高潮| 国产欧美亚洲国产| 97人妻精品一区二区三区麻豆| 欧美精品国产亚洲| 国语对白做爰xxxⅹ性视频网站| 高清毛片免费看| 国产探花极品一区二区| 亚洲精品日韩在线中文字幕| 久久久久久国产a免费观看| av女优亚洲男人天堂| 天堂网av新在线| 一级毛片黄色毛片免费观看视频| 街头女战士在线观看网站| 少妇的逼好多水| 精品人妻熟女av久视频| 99热这里只有是精品50| 免费av毛片视频| 精品人妻熟女av久视频| 久久精品国产a三级三级三级| av在线亚洲专区| freevideosex欧美| 国产精品三级大全| 麻豆成人午夜福利视频| 97在线人人人人妻| 国产毛片a区久久久久| 国产精品国产三级专区第一集| 五月玫瑰六月丁香| av国产久精品久网站免费入址| 极品教师在线视频| 亚洲,欧美,日韩| 2022亚洲国产成人精品| 久久人人爽人人爽人人片va| 日韩免费高清中文字幕av| 精品99又大又爽又粗少妇毛片| 99精国产麻豆久久婷婷| 哪个播放器可以免费观看大片| 久久久久久国产a免费观看| 久久精品夜色国产| 可以在线观看毛片的网站| 亚洲av欧美aⅴ国产| 日本午夜av视频| 黄色怎么调成土黄色| 女人被狂操c到高潮| 亚洲av中文字字幕乱码综合| 午夜福利高清视频| 国产视频首页在线观看| 国产亚洲一区二区精品| 国产欧美亚洲国产| 亚洲美女视频黄频| 六月丁香七月| 成年免费大片在线观看| 日韩欧美一区视频在线观看 | 国产成人精品婷婷| 亚洲精品第二区| 亚洲精品一二三| 黄片无遮挡物在线观看| 久久6这里有精品| 直男gayav资源| 三级国产精品欧美在线观看| 听说在线观看完整版免费高清| 91精品国产九色| 99re6热这里在线精品视频| 97人妻精品一区二区三区麻豆| 亚洲精品久久午夜乱码| 欧美成人精品欧美一级黄| 岛国毛片在线播放| 亚洲精品成人久久久久久| 偷拍熟女少妇极品色| 人妻系列 视频| 尾随美女入室| 一区二区三区精品91| 成人漫画全彩无遮挡| 欧美3d第一页| 天天一区二区日本电影三级| 国产 一区精品| 91在线精品国自产拍蜜月| 国产v大片淫在线免费观看| 日本熟妇午夜| 少妇丰满av| videossex国产| 在线观看人妻少妇| 亚洲av欧美aⅴ国产| 又粗又硬又长又爽又黄的视频| 成年人午夜在线观看视频| 国产在线男女| 免费观看a级毛片全部| av卡一久久| 中文字幕久久专区| 久久久亚洲精品成人影院| 国产高清有码在线观看视频| 丝瓜视频免费看黄片| 夫妻性生交免费视频一级片| 日韩伦理黄色片| 禁无遮挡网站| 国产在线男女| 2022亚洲国产成人精品| av卡一久久| 直男gayav资源| 日产精品乱码卡一卡2卡三| 欧美一区二区亚洲| 亚洲精品456在线播放app| 亚洲国产精品999| 我的老师免费观看完整版| 777米奇影视久久| 青春草国产在线视频| 九草在线视频观看| 爱豆传媒免费全集在线观看| 少妇熟女欧美另类| 亚洲成人av在线免费| 日本猛色少妇xxxxx猛交久久| 99热这里只有是精品在线观看| 亚洲在久久综合| 少妇人妻久久综合中文| 热99国产精品久久久久久7| 午夜视频国产福利| 午夜福利高清视频| 日本爱情动作片www.在线观看| 欧美极品一区二区三区四区| 人体艺术视频欧美日本| 一级片'在线观看视频| 99热全是精品| 少妇高潮的动态图| av免费在线看不卡| 在线免费十八禁| 久久久久久久久久成人| 黄片wwwwww| 亚洲欧美清纯卡通| 精品久久久久久久人妻蜜臀av| 欧美日韩视频精品一区| 欧美成人a在线观看| 真实男女啪啪啪动态图| 久久久久久九九精品二区国产| 午夜免费鲁丝| 国产在线一区二区三区精| 国产午夜福利久久久久久| 亚洲欧洲日产国产| 99热这里只有精品一区| 永久免费av网站大全| 超碰av人人做人人爽久久| 精品久久久噜噜| 免费观看a级毛片全部| 精品久久久精品久久久| 小蜜桃在线观看免费完整版高清| 久久99精品国语久久久| 亚洲国产精品成人综合色| 成人欧美大片| 久久精品久久久久久噜噜老黄| 亚洲欧美中文字幕日韩二区| 亚洲无线观看免费| 国产精品国产三级国产av玫瑰| 狂野欧美激情性bbbbbb| 伦理电影大哥的女人| 精品久久久久久久久av| 久热久热在线精品观看| 成人毛片60女人毛片免费| 69人妻影院| 日韩视频在线欧美| 日韩欧美精品v在线| 久久久色成人| 亚洲色图av天堂| 国产精品爽爽va在线观看网站| 欧美丝袜亚洲另类| 色视频在线一区二区三区| 亚洲人成网站在线播| 寂寞人妻少妇视频99o| 校园人妻丝袜中文字幕| 最近最新中文字幕大全电影3| 亚洲精品自拍成人| 亚洲精品影视一区二区三区av| 性色avwww在线观看| 国产午夜精品一二区理论片| 久久精品久久久久久噜噜老黄| 国产老妇伦熟女老妇高清| 精品少妇黑人巨大在线播放| 亚洲一级一片aⅴ在线观看| 狠狠精品人妻久久久久久综合| 日韩人妻高清精品专区| 亚洲精品国产av成人精品| 特级一级黄色大片| 亚洲国产欧美在线一区| 在线亚洲精品国产二区图片欧美 | 成年女人看的毛片在线观看| 免费观看性生交大片5| 在线观看人妻少妇| 五月伊人婷婷丁香| 国产精品一区www在线观看| 国产午夜精品一二区理论片| 日韩大片免费观看网站| 中文字幕制服av| 亚洲精品自拍成人| 2021少妇久久久久久久久久久| 久久鲁丝午夜福利片| 夫妻午夜视频| 夜夜爽夜夜爽视频| www.色视频.com| 国产乱人偷精品视频| 亚洲成人精品中文字幕电影| 18禁裸乳无遮挡免费网站照片| 欧美+日韩+精品| 国产黄a三级三级三级人| 免费黄网站久久成人精品| 亚洲激情五月婷婷啪啪| 国语对白做爰xxxⅹ性视频网站| 国产成人一区二区在线| 久久久国产一区二区| 亚洲人成网站在线播| 国产黄色免费在线视频| 禁无遮挡网站| 欧美激情久久久久久爽电影| 一级毛片电影观看| 丝袜喷水一区| 日韩中字成人| 久久人人爽人人片av| 亚洲欧美一区二区三区黑人 | 免费大片18禁| 欧美潮喷喷水| 亚洲av.av天堂| 中文字幕制服av| 国产亚洲5aaaaa淫片| 国产亚洲精品久久久com| 大香蕉久久网| 在线观看国产h片| 国产日韩欧美在线精品| 精品一区二区免费观看| 国产一级毛片在线| 久久久亚洲精品成人影院| 免费观看的影片在线观看| 三级男女做爰猛烈吃奶摸视频| 校园人妻丝袜中文字幕| 亚洲无线观看免费| 一级毛片电影观看| 99久久精品一区二区三区| 各种免费的搞黄视频| 女的被弄到高潮叫床怎么办| 汤姆久久久久久久影院中文字幕| 久久久久网色| 国产高清不卡午夜福利| 人妻夜夜爽99麻豆av| av卡一久久| 涩涩av久久男人的天堂| 日韩中字成人| 国产精品久久久久久精品古装| 亚洲av国产av综合av卡| 麻豆成人午夜福利视频| 精品国产一区二区三区久久久樱花 | 少妇 在线观看| 日本免费在线观看一区| 国产精品久久久久久av不卡| 国产一区二区三区综合在线观看 | 国产精品久久久久久久电影| 美女cb高潮喷水在线观看| 色综合色国产| 校园人妻丝袜中文字幕| 91狼人影院| 欧美性感艳星| 在线播放无遮挡| 美女xxoo啪啪120秒动态图| 中文资源天堂在线| 在线观看国产h片| 尾随美女入室| 青青草视频在线视频观看| 国产伦在线观看视频一区| 偷拍熟女少妇极品色| 高清视频免费观看一区二区| 在线观看美女被高潮喷水网站| 搞女人的毛片| 观看美女的网站| 人妻制服诱惑在线中文字幕| 午夜免费鲁丝| 国产一区二区三区综合在线观看 | 国产探花极品一区二区| av在线天堂中文字幕| 波多野结衣巨乳人妻| 噜噜噜噜噜久久久久久91| 18+在线观看网站| 国产视频首页在线观看| 亚洲无线观看免费| 青青草视频在线视频观看| 少妇的逼水好多| 夫妻午夜视频| 亚洲av中文字字幕乱码综合| 国产成人福利小说| 久久精品熟女亚洲av麻豆精品| 国产亚洲91精品色在线| 免费少妇av软件| 大码成人一级视频| 成人综合一区亚洲| 啦啦啦在线观看免费高清www| 老师上课跳d突然被开到最大视频| 精品久久久久久电影网| 国产在线一区二区三区精| 少妇被粗大猛烈的视频| 特大巨黑吊av在线直播| 久久国产乱子免费精品| 亚洲精品成人av观看孕妇| 欧美最新免费一区二区三区| 天美传媒精品一区二区| 中国美白少妇内射xxxbb| 亚洲一级一片aⅴ在线观看| 91精品国产九色| 美女主播在线视频| 国产爽快片一区二区三区| 久久精品久久久久久噜噜老黄| 久久精品国产a三级三级三级| 亚洲av男天堂| 成人综合一区亚洲| 欧美少妇被猛烈插入视频| 日韩在线高清观看一区二区三区| 99九九线精品视频在线观看视频| 欧美激情国产日韩精品一区| 国产精品久久久久久av不卡| 午夜福利在线观看免费完整高清在|